S&P Futures
3,996.75 +13.75 (+0.35%) Dow Futures
32,553.00 +97.00 (+0.30%) Nasdaq Futures
12,722.00 +33.50 (+0.26%) Russell 2000 Futures
1,773.40 +12.70 (+0.72%) Crude Oil
68.19 +0.55 (+0.81%) Gold
1,971.80 -11.00 (-0.55%)
GE HealthCare Technologies Inc. (GEHC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 75.84 |
| Open | 75.49 |
| Bid | 74.50 x 1000 |
| Ask | 79.90 x 800 |
| Day's Range | 74.51 - 75.81 |
| 52 Week Range | 53.00 - 78.76 |
| Volume | |
| Avg. Volume | 3,309,496 |
| Market Cap | 34.486B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 18.21 |
| EPS (TTM) | 4.13 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 90.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GEHC
Related Research
- GE HealthCare Technologies Inc.GEHC: What does Argus have to say about GEHC?GE HEALTHCARE TECHNOLOGY has an Investment Rating of BUY; a target price of $84.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Low.RatingFair ValueEconomic Moat6 days agoArgus Research
- Yahoo Finance
GE stock has skyrocketed 80% in 5 months — JPMorgan says that's a problem
GE's stock is too richly valued, warns the influential JPM coverage team.
- Business Wire
Advantus Health Partners and GE HealthCare Announce Multi-Year Agreement to Expand Access to Healthcare Technology Management Services
CINCINNATI & CHICAGO, March 02, 2023--Advantus Health Partners, a health care solutions company delivering more effective, efficient supply chain models to health care organizations, and GE HealthCare (Nasdaq: GEHC), one of the largest providers of medical equipment maintenance services in the world, announced an agreement of up to $760M over 10-years to provide GE HealthCare’s Healthcare Technology Management (HTM) services to Advantus Health Partners’ clients.
- Business Wire
GE HealthCare Announces Completion of Phase I Subject Recruitment in Early Clinical Development Program for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent
CHALFONT ST GILES, England, March 01, 2023--Phase I Completion for Early Clinical Development Program for First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent
